Always consult with your provider to review your medical history
Although they are usually not a significant concern, common ones like nausea, diarrhea, or appetite loss might occur
Currently, a phase II trial (NCT05350969) is ongoing to evaluate the potential of CDR132L to prevent or reverse cardiac remodeling in patients with HFrEF following MI
Rule 1 Never Use an Unspecified Code When a Specific One Fits
#PharmaIndustry #IndianPharma #HealthcareIndia #PharmaMarketing #MedicalSales #PharmaBrands #IndiaHealthcare #LifeSciences #LinkedInPost To view or add a comment, sign in Big Update for Healthcare in India Semaglutide Patent Expiry (March-2026) One of the most significant upcoming patent expiries is Semaglutide, a blockbuster drug widely used for Type-2 Diabetes and Obesity (brands such as Ozempic and Wegovy)
82104307), Natural Science Foundation of Hunan Province (No